[COVID-19 and stroke]

Rinsho Shinkeigaku. 2020 Dec 26;60(12):822-839. doi: 10.5692/clinicalneurol.cn-001529. Epub 2020 Nov 20.
[Article in Japanese]

Abstract

Due to the pandemic of corona virus disease 2019 (COVID-19), the stroke medical care system is unavoidably undergoing major changes such as a decrease in the number of stroke patients receiving consultation, delay in consultation, and a decrease in the number of intravenous thrombolysis and mechanical thrombectomy procedures. Stroke incidence in COVID-19 patients is approximately 1.1%. The features of stroke with COVID-19 have been elucidated: higher incidence in ischemic stroke than hemorrhagic stroke, increasing number of young patients, high D-dimer levels, and higher risk in elderly patients with cardiovascular risk factors such as hypertension and diabetes. In patients with COVID-19, venous thromboembolism is more common than arterial thromboembolism, and stroke is more common than acute coronary syndrome. Protected code stroke (PCS) has been proposed which provides safe, effective and prompt treatment under complete infection control.

Keywords: COVID-19; cryptogenic stroke; large vessel occlusion; protected code stroke; stroke.

Publication types

  • Review

MeSH terms

  • Acute Coronary Syndrome / complications
  • COVID-19 / complications*
  • Diabetes Mellitus
  • Fibrin Fibrinogen Degradation Products / analysis
  • Humans
  • Hypertension
  • Pandemics
  • Risk Factors
  • Stroke / complications*
  • Stroke / therapy*
  • Thrombectomy / statistics & numerical data
  • Thrombolytic Therapy / statistics & numerical data
  • Venous Thromboembolism / complications

Substances

  • Fibrin Fibrinogen Degradation Products
  • fibrin fragment D